Bringing the fundamentals into focus…
Back to Inhibikase Therapeutics, Inc.
How Inhibikase Therapeutics, Inc. stacks up
IKT · against 557 other Healthcare companies listed in US-listed
Profitability
17/ 100
Below the middle of the pack.
Ranked #365 of 558 · scores higher than 33% of peers
Bars: peers in each 10-point band of the profitability score114 peers with a profitability score of 10–19, including IKT · Click a bar to see the companies
Why profitability scores 17?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on assets and return on invested capital, which are weaker than most Healthcare peers.
- a lower return on assets: weaker than 89% of peers. Return on assets: -37.1% vs peer median 1.7%
- a lower return on invested capital: weaker than 86% of peers. Return on invested capital: -42.3% vs peer median 4.7%
- Operating margin is not reported, so it is left out of the score.
Metric by metric
Position: dot = IKT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | IKT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 517 reported | -42.3% | -7.0% | 28% | 33% | |
| Operating marginHigher is better · 479 reported | Not reported | -2.4% | — | — | 33% |
| Return on assetsHigher is better · 582 reported | -37.1% | -7.8% | 22% | 33% | |
| Return on equityHigher is better · 531 reported | -52.0% | -19.7% | 28% | Context only | |
| Gross marginHigher is better · 601 reported | 0.0% | 43.9% | 6% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around IKT| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 595M USD | 99 | 97 | |
| 1 | 433M USD | 99 | 81 | |
| 1 | 17.9B USD | 99 | 76 | |
| 1 | 52.9B USD | 99 | 57 | |
| 1 | 578M USD | 99 | 73 | |
| 365 | 593M USD | 17 | 40 | |
| 365 | 479M USD | 17 | 34 | |
| 365 | 393M USD | 17 | 50 | |
| 365 | Unavailable | 17 | 56 | |
| 365 | 207M USD | 17 | 41 | |
| 365 | 255M USD | 17 | 38 | |
| 365 | 1.9B USD | 17 | 32 | |
| 365 | 276M USD | 17 | 46 | |
| 365 | 519M USD | 17 | 22 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score